ADAP
Closed
Adaptimmune Therapeutics Plc
0.2319
-0.0078 (-3.25%)
Last Update: 01 Jul 2025 23:14:00
Yesterday: 0.2397
Day's Range: 0.2306 - 0.2486
Send
sign up or login to leave a comment!
When Written:
1.095
Adaptimmune Therapeutics Plc is a clinical-stage biotechnology company that focuses on developing novel immunotherapies for cancer. The company's proprietary T-cell receptor (TCR) platform enables the identification of cancer targets and the generation of TCRs to attack these targets. Adaptimmune's lead product candidate, ADP-A2M4, is being evaluated in multiple clinical trials for the treatment of solid tumors. The company has partnerships with several pharmaceutical companies, including GSK and Astellas, to develop additional TCR therapies. Adaptimmune is headquartered in Oxfordshire, UK, and has a presence in the US. The company was founded in 2008 and went public in 2015.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








